Camlin Fine Sciences Limited has informed the Exchange regarding Outcome of Board Meeting held on September 29, 2025.
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Camlin Fine Sciences, at its meeting on September 29, 2025, approved the issuance of 41,06,181 fully paid-up equity shares at ₹247.69 per share (including a premium of ₹246.69), aggregating to about ₹101.71 crores. This is a preferential issue on a private placement basis to five investors — Cyrille Damany, Philippe Le Ray, Alexandre Moranville, Chris Project, and Saffelberg Investments. The shares are being allotted as non-cash consideration under a share swap arrangement to acquire approximately 78.68% of Vinpai, a French société anonyme, pursuant to a share purchase agreement dated February 24, 2025. Post-issue, the allottees will collectively hold about 2.14% in Camlin Fine Sciences. The Board also approved a Postal Ballot process to seek shareholder approval for the preferential issue.
This is a non-cash, share-swap-based acquisition that will dilute existing shareholders by about 2.14% but gives Camlin Fine Sciences a majority stake in a French company, expanding its international footprint. The deal is subject to shareholder approval via Postal Ballot, making it a key event for investors to monitor.